ArticleBMC medical research methodology2018
A dynamic Bayesian Markov model for health economic evaluations of interventions in infectious disease.
Article in BMC medical research methodology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review.PharmacoEconomics · 2021Pooled it
- Economic and epidemiological evaluation of text message-based interventions in patients with the Human Immunodeficiency Virus.Revista latino-americana de enfermagem · 2020Trial
- Modelling the epidemic dynamics of HPV among women in China and optimization of ongoing cervical cancer elimination strategies.BMC medicine · 2026Article
- Incorporating Additional Evidence as Prior Information to Resolve Non-Identifiability in Bayesian Disease Model Calibration: A Tutorial.Statistics in medicine · 2025Article
- Cervical cancer screening by cotesting method for Vietnamese women 25-55 years old: a cost-effectiveness analysis.BMJ open · 2025Article
- Cost-effectiveness of cervical cancer screening and HPV vaccination: a Markov model from the healthcare payer perspective.Frontiers in public health · 2025Article
- Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China.Children (Basel, Switzerland) · 2024Article
- Framework for determining the optimal course of action when efficiency and affordability measures differ by perspective in cost-effectiveness analysis-with an illustrative case of HIV treatment in Mozambique.Cost effectiveness and resource allocation : C/E · 2023Article
- Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study.BMC medicine · 2023Article
- HIV Rapid Testing in the General Population and the Usefulness of PrEP in Ecuador: A Cost-Utility Analysis.Frontiers in public health · 2022Article
- Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study.BMC medicine · 2021Article
- Article
- On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers.Frontiers in public health · 2020Article
- Assessing type I error and power of multistate Markov models for panel data-A simulation study.Communications in statistics: Simulation and computation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth economic evaluations of interventions in infectious disease are commonly based on the predictions of ordinary differential equation (ODE) systems or Markov models (MMs). Standard MMs are static, whereas ODE systems are usually dynamic and account for herd immunity which is crucial to prevent overestimation of infection prevalence. Complex ODE systems including distributions on model parameters are computationally intensive. Thus, mainly ODE-based models including fixed parameter values are presented in the literature. These do not account for parameter uncertainty. As a consequence, probabilistic sensitivity analysis (PSA), a crucial component of health economic evaluations, cannot be conducted straightforwardly.
methodsWe present a dynamic MM under a Bayesian framework. We extend a static MM by incorporating the force of infection into the state allocation algorithm. The corresponding output is based on dynamic changes in prevalence and thus accounts for herd immunity. In contrast to deterministic ODE-based models, PSA can be conducted straightforwardly. We introduce a case study of a fictional sexually transmitted infection and compare our dynamic Bayesian MM to a deterministic and a Bayesian ODE system. The models are calibrated to simulated time series data.
resultsBy means of the case study, we show that our methodology produces outcome which is comparable to the "gold standard" of the Bayesian ODE system.
conclusionsIn contrast to ODE systems in the literature, the dynamic MM includes distributions on all model parameters at manageable computational effort (including calibration). The run time of the Bayesian ODE system is 15 times longer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.